2023
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefit
1997
The early detection of prostate carcinoma with prostate specific antigen
Smith D, Humphrey P, Catalona W. The early detection of prostate carcinoma with prostate specific antigen. Cancer 1997, 80: 1852-1856. PMID: 9351559, DOI: 10.1002/(sici)1097-0142(19971101)80:9<1852::aid-cncr25>3.0.co;2-3.Peer-Reviewed Original ResearchConceptsDigital rectal examinationSubset of menPositive predictive valueSignificant carcinomaPSA levelsRectal examinationProstate carcinomaPredictive valueScreening testDigital rectal examination resultsIntermediate outcomesCarcinoma detection rateEarly prostate carcinomaScreen-detected carcinomasScreen-detected tumorsInitial PSA levelReasonable positive predictive valueMajority of tumorsProstate-specific antigenProportion of menPathologic characteristicsClinicopathologic featuresPathologic featuresProstatic biopsyDisease stage